EpimAb Biotherapeutics
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6th Floor Building 2 Jinchuang Building ...Phone Number
+86 2161951000Website
www.epimab.comRevenue
$6.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About EpimAb Biotherapeutics
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou. Established in 2015, EpimAb Biotherapeutics is headquartered in Shanghai, China.Explore more
EpimAb Biotherapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EpimAb Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at EpimAb Biotherapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once EpimAb Biotherapeutics has new funding data
Product Launch: Get notified when EpimAb Biotherapeutics launches new products
Earning: See what the market has to say on EpimAb Biotherapeutics recently announced quarterly report
EpimAb Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if EpimAb Biotherapeutics is spiking on competitors!
Click to see if EpimAb Biotherapeutics had a recent Job posting/layoffs
Check if EpimAb Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at EpimAb Biotherapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
EpimAb Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EpimAb Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EpimAb Biotherapeutics.
EpimAb Biotherapeutics financials insights
Gather financial insights about EpimAb Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$25M
2019
Series B
$74M
2021
Series C
$120M
EpimAb Biotherapeutics Tech Stack
A closer look at the technologies used by EpimAb Biotherapeutics
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Left Company
Executive Move
New Hire
Executive Move
New Hire
Executive Move
EpimAb Biotherapeutics News & Media
EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall
SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the achievement of a first CTA Filing by Almirall (www.almirall.com) under the license agreement between the companies completed in 2023.Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into a Worldwide Licensing Agreement for KLK2-Directed T-Cell Engager in Metastatic Prostate Cancer
Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into Worldwide Licensing Agreement for KLK2-Directed T-Cell EngagerEpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual Meeting
SHANGHAI, April 01, 2025 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce the company will be presenting four poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago, Illinois, from April 25-30, 2025, at the McCormick Place Convention Center.Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EpimAb Biotherapeutics
Sign Up For FreeTo access detailed company insights
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou. Established in 2015, EpimAb Biotherapeutics is headquartered in Shanghai, China.... Read More
